Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
FUJIFILM Biotechnologies Unveils ShunzymeX™ precision purification technology
Wednesday, March 04, 2026FUJIFILM Biotechnologies a world leading contract development and manufacturing organization CDMO for biologics vaccines and advanced therapies today unveils ShunzymeX precision purification technology
T-knife Therapeutics Announces Authorization of Clinical Trial Application for TK-6302, A Multi-Armored, CRISPR based T cell Therapy for Solid Tumors
Wednesday, March 04, 2026Tknife Therapeutics Inc a biopharmaceutical company developing nextgeneration T cell therapies to fight cancer today announced the authorization of its Clinical Trial Application CTA to begin the Phase ATLAS trial of TK in Europe
Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris
Tuesday, March 03, 2026Thermo Fisher Scientific the world leader in serving science today announced the launch of Thermo Scientific Brilliance Candida Agar and Spectra Candida Agar new colorbased chromogenic culture media
Advancing Influenza Vaccine Development: Sino Biological Launches Antigens for the 2026-2027 Northern Hemisphere Influenza Vaccine Strains
Tuesday, March 03, 2026The World Health Organization WHO has announced its recommendations for the Northern Hemisphere influenza vaccine composition The update highlights two key developments the continued spread of A HN subclade
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
Friday, February 27, 2026Synthekine Inc an engineered cytokine therapeutics company today announced that it has entered into a clinical trial collaboration and supply agreement with Merck known as MSD outside of the United States and Canada
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
Thursday, February 26, 2026Novartis a leading global innovative medicines company today announced plans to establish a new squarefoot radioligand therapy RLT manufacturing site in Denton Texas
Siren Biotechnology Receives FDA Fast Track Designation for SRN-101 for the Treatment of Recurrent High-Grade Glioma
Wednesday, February 25, 2026Siren Biotechnology pioneers of Universal AAV ImmunoGene Therapy for cancer today announced that the US Food and Drug Administration FDA has granted Fast Track Designation to SRN the Companys
PlantArcBio and Helix Sementes e Biotecnologia (Agroceres Group Company) Announce Licensing Collaboration to Advance High-Yield, Drought-Resilient Corn in South America
Tuesday, February 24, 2026PlantArcBio an agbiotechnology company pioneering precision biology for better crop performance and Helix Sementes e Biotecnologia a corn and sorghum seed company within Agroceres Group
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
Friday, February 20, 2026Genentech a member of the Roche Group announced today that the US Food and Drug Administration FDA has approved the combination regimen of Venclexta venetoclax plus acalabrutinib for the treatment of previously
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development
Thursday, February 19, 2026Evinova today announced strategic collaborations with global life sciences companies Astellas Pharma Inc Astellas AstraZeneca and Bristol Myers Squibb to accelerate their global clinical development using
